Clinical application study of bone marrow immunoscintigraphy using 99mTc-labelled anti-granulocyte monoclonal antibody BW250/183

Objective: To study: (1) The labelling method of 99mTc-BW250/183 and its organ distribution pattern after injection. (2) The clinical value of bone marrow immunoscintigraphy of evaluation of patients with aplastic anemia. (3) The clinical value of bone marrow immunoscintigraphy of determination of bone metastasis. Methods: (1) Whole body imaging was performed to one volunteer after injection of 555 MBq 99mTc-BW250/183, meanwhile, 2 ml blood samples was taken from a cubital vein. The percentage of radioactivity of different organs and the kinetic data of in-vivo 99mTc-BW250/183 was then calculated. In all the blood samples the peripheral leukocytes were counted by a standard procedure. (2) Bone marrow immunoscintigraphy were performed to 8 patients with aplastic anemia 4 h after injection of 99mTc-BW250/183, 6 of them also underwent bone marrow imaging with 99mTc-SC. (3) Bone marrow immunoscintigraphy and conventional bone scan were performed to 14 patients with suspected bone metastases to detect bone metastases. The results was compared with X-ray, X-CT or MRI. Results: 99mTc-BW250/183 is a safe and ideal bone marrow imaging agent. Bone marrow immunoscintigraphy plays an important role in evaluating patients with aplastic anemia and determining bone metastases